Cargando…
Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the pro...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511026/ https://www.ncbi.nlm.nih.gov/pubmed/36172370 http://dx.doi.org/10.3389/fimmu.2022.932559 |